These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29990501)

  • 1. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
    Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
    Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRN2 is a non-canonical melanoma tumor-suppressor.
    Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
    Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor.
    Boyle GM; Woods SL; Bonazzi VF; Stark MS; Hacker E; Aoude LG; Dutton-Regester K; Cook AL; Sturm RA; Hayward NK
    Pigment Cell Melanoma Res; 2011 Jun; 24(3):525-37. PubMed ID: 21435193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
    Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
    Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.
    Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG
    EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Met amplification and tumor progression in Cdkn2a-deficient melanocytes.
    Vanbrocklin MW; Robinson JP; Whitwam T; Guilbeault AR; Koeman J; Swiatek PJ; Vande Woude GF; Khoury JD; Holmen SL
    Pigment Cell Melanoma Res; 2009 Aug; 22(4):454-60. PubMed ID: 19422607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.
    Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
    Hum Pathol; 2004 Jan; 35(1):25-33. PubMed ID: 14745721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
    McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
    Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected High Levels of BRN2/POU3F2 Expression in Human Dermal Melanocytic Nevi.
    Chitsazan A; Lambie D; Ferguson B; Handoko HY; Gabrielli B; Walker GJ; Boyle GM
    J Invest Dermatol; 2020 Jun; 140(6):1299-1302.e4. PubMed ID: 31881210
    [No Abstract]   [Full Text] [Related]  

  • 10. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
    Herbert K; Binet R; Lambert JP; Louphrasitthiphol P; Kalkavan H; Sesma-Sanz L; Robles-Espinoza CD; Sarkar S; Suer E; Andrews S; Chauhan J; Roberts ND; Middleton MR; Gingras AC; Masson JY; Larue L; Falletta P; Goding CR
    Genes Dev; 2019 Mar; 33(5-6):310-332. PubMed ID: 30804224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells.
    Ellmann L; Joshi MB; Resink TJ; Bosserhoff AK; Kuphal S
    Lab Invest; 2012 Dec; 92(12):1788-800. PubMed ID: 23069940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.
    Berlin I; Denat L; Steunou AL; Puig I; Champeval D; Colombo S; Roberts K; Bonvin E; Bourgeois Y; Davidson I; Delmas V; Nieto L; Goding CR; Larue L
    Mol Cell Biol; 2012 Apr; 32(7):1237-47. PubMed ID: 22290434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. POU transcription factors in melanocytes and melanoma.
    Besch R; Berking C
    Eur J Cell Biol; 2014; 93(1-2):55-60. PubMed ID: 24315688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRN2, a POUerful driver of melanoma phenotype switching and metastasis.
    Fane ME; Chhabra Y; Smith AG; Sturm RA
    Pigment Cell Melanoma Res; 2019 Jan; 32(1):9-24. PubMed ID: 29781575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.
    Bonvin E; Falletta P; Shaw H; Delmas V; Goding CR
    Mol Cell Biol; 2012 Nov; 32(22):4674-83. PubMed ID: 22988297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination.
    Pinner S; Jordan P; Sharrock K; Bazley L; Collinson L; Marais R; Bonvin E; Goding C; Sahai E
    Cancer Res; 2009 Oct; 69(20):7969-77. PubMed ID: 19826052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.
    Daniotti M; Ferrari A; Frigerio S; Casieri P; Miselli F; Zucca E; Collini P; Della Torre G; Manoukian S; Peissel B; Bono A; Santinami M; Parmiani G; Rivoltini L; Pilotti S; Rodolfo M
    J Invest Dermatol; 2009 Jul; 129(7):1759-68. PubMed ID: 19158841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CDKN2A (p16INK4A/p14ARF) Over-Expression on Proliferation and Migration of Human Melanoma A375 Cells.
    Bai M; Yu NZ; Long F; Feng C; Wang XJ
    Cell Physiol Biochem; 2016; 40(6):1367-1376. PubMed ID: 27997910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
    Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
    Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
    Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
    Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.